We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Bo Ahrén

Bo Ahrén MD

Bo Ahrén received his MD at Lund University. Since 1999 he holds the position of professor in Clinical Metabolic Research at Lund University and consultant at the Department of Endocrinology at Skåne University Hospital. He was the Chief Physician at the County of Skåne in 2004-2005 and the Dean of the Faculty of Medicine, Lund University 2006-2011. Bo Ahrén is also an associate editor of Diabetologia, member of the Council of European Association for the Study of Diabetes (EASD) and chairman of the EASD meeting in 2015 in Stockholm.

Dr Ahrén has published several original articles and review articles within the area of islet function. He has combined basic science with clinically oriented research to focus on islet function, with the special aim to understand the regulation and mechanism of normal islet function and the mechanisms and consequences of islet dysfunction as an important factor underlying type 2 diabetes. Dr Ahrén has also worked to develop new targets and compounds for the treatment of type 2 diabetes. In this area, Dr Ahrén has during many years concentrated on incretin actions with particular emphases on developing new treatment based on the incretin hormone GLP-1 and its inactivation enzyme, dipeptidyl peptidase-4 (DPP-4).

Disclosures

Dr Ahrén declares potential dualities of interest in the field due to receive of honoraria for lecturing and/or grants for research from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Lilly, Merck,Novartis, Novo Nordisk, Sanofi and Takeda, which all are companies involved in production of incretin-based therapy.